BRISTOL, TN — October 7, 2025 — Leads & Copy — Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) is reshaping the biotechnology landscape by integrating clinical innovation, consumer health commercialization, and advanced market infrastructure.
The company’s foundation is in neuroscience, with its Lucid-MS program targeting multiple sclerosis. In collaboration with Massachusetts General Hospital, Quantum is conducting an imaging study to monitor remyelination in vivo.
Quantum has aligned its operations around three verticals: biopharmaceutical development, consumer health commercialization through Celly Nu’s unbuzzd™ beverage, and market access innovation using modern trading and settlement technology.
In January 2025, Quantum’s shares were approved for dual listing on Upstream, a regulated digital exchange, underscoring the company’s commitment to accessibility and modernization.
Quantum’s leadership views its next-generation listing strategy and capital design as extensions of the precision that drives its research pipeline.
Quantum BioPharma is positioning itself as a next-generation issuer, aligning scientific credibility, operational transparency, and shareholder connectivity.
Kristen Owens
info@vanderbiltreport.com
Source: Quantum BioPharma Ltd
